Literature DB >> 27553460

Cardiac implantable electronic device infection due to Mycobacterium species: a case report and review of the literature.

Bandar Al-Ghamdi1,2, Hassan El Widaa3, Maie Al Shahid3, Mohammed Aladmawi3, Jawaher Alotaibi4, Aly Al Sanei3, Magid Halim4,5.   

Abstract

BACKGROUND: Infection of cardiac implantable electronic devices is a serious cardiovascular disease and it is associated with a high mortality. Mycobacterium species may rarely cause cardiac implantable electronic devices infection. CASE
PRESENTATION: We are reporting a case of miliary tuberculosis in an Arab patient with dilated cardiomyopathy and a cardiac resynchronization therapy-defibrillator device that was complicated with infection of his cardiac resynchronization therapy-defibrillator device. To our knowledge, this is the third case in the literature with such a presentation and all patients died during the course of treatment. This underscores the importance of early diagnosis and management. We also performed a literature review of reported cases of cardiac implantable electronic devices infection related to Mycobacterium species.
CONCLUSIONS: Cardiac implantable electronic devices infection due to Mycobacterium species is an uncommon but a well-known entity. Early diagnosis and prompt management may result in a better outcome.

Entities:  

Keywords:  Defibrillator; Endocarditis; Infection; Mycobacterium; Pacemaker

Mesh:

Year:  2016        PMID: 27553460      PMCID: PMC4995631          DOI: 10.1186/s13104-016-2221-1

Source DB:  PubMed          Journal:  BMC Res Notes        ISSN: 1756-0500


Background

Infection of cardiac implantable electronic devices (CIEDs) is a serious cardiovascular disease and it is associated with a high mortality. CIEDs infection may occur as a pocket infection or as infection on the leads with infective endocarditis. Cardiac device-related infective endocarditis (CDR-IE) may occur as a primary infection of the CIED system or as a secondary infection as a result of hematogenous seeding during a bacteremia secondary to a distant infected focus [1]. Mycobacterium tuberculosis (TB) is an infection that primarily affects the lungs, but it can involve any other organs and structures such as the kidney, spine, brain, and rarely the heart. TB disease can be fatal if not treated properly (http://www.cdc.gov). Tuberculosis endocarditis (TBE) has been reported for many years with involvement of native or prosthetic valves mostly in cases of miliary TB [2]. Mycobacterium species are another uncommon but well-described pathogen in CIED infections [3]. We are reporting a case of miliary TB in an Arab patient with dilated cardiomyopathy and a cardiac resynchronization therapy-defibrillator (CRT-D) device. His condition was complicated with TB meningitis and a CDR-IE with vegetations on the leads. He underwent surgical removal of the CRT-D device and leads and a gram stain of the vegetations was positive for acid-fast bacilli (AFB). We also performed a literature review of reported cases with Mycobacterium species related CIEDs infection.

Case presentation

A 50-year-old male Arab patient with non-ischemic dilated cardiomyopathy, biventricular failure with left ventricular ejection fraction (LVEF) of 20 %, moderate to severe mitral regurgitation and tricuspid regurgitation, left bundle branch block, and non-sustained ventricular tachycardia. Cardiac catheterization did not show any significant coronary artery disease. He underwent a CRT-D device implantation, as he was symptomatic with shortness of breath, New York Heart Association Functional Classification-II. He had no history of diabetes mellitus, hypertension, or dyslipidemia. He was on anti-heart failure medications and was on the heart transplantation list. He presented to the Emergency Department 8 months after CRT-D device implantation with 2 months’ history of high-grade fever, chills, rigors, and weight loss. There was no history of concomitant respiratory, gastroenterology, cardiovascular, or neurologic localizing symptoms. There was no history of contact with febrile or TB patients. He was seen at another medical center and started on intravenous (IV) vancomycin and gentamicin for possible infective endocarditis involving his CRT-D device leads but with no improvement. On presentation, he was looking chronically ill but not in acute distress. He was febrile with a temperature of 38.8 °C, but he was hemodynamically stable with a blood pressure of 107/57 mm Hg, and heart rate of 98 beats per minute. Oxygen saturation was 92–94 % on room air. Cardiovascular exam showed a jugular venous pressure (JVP) at 4 cm above the sternal angle; normal first and second heart sounds with a soft systolic murmur at left lower sternal border which was reported in his previous physical exam. The device site in the left upper chest was normal. There was no lower limb edema and no stigmata of infective endocarditis. Chest exam showed bilateral basal crepitations. Neurological exam was unremarkable. Laboratory tests; CBC showed mild anemia, and thrombocytopenia with normal white blood count. Renal profile was normal and hepatic profile showed mild elevation of aspartate aminotransferase (AST) and total bilirubin, and low albumin. Cardiac enzymes showed mild elevation of Troponin T. Lactic acid was elevated. Laboratory test values are summarized in Table 1. The 12 lead electrocardiogram showed sinus tachycardia at 106 beats per minute with atrial sensed and biventricular paced rhythm.
Table 1

Laboratory test results on admission

TestPatient’s valueNormal range
CBC
 WBC6.11 109/L3.90–11.00
 Hb107 g/L135–180
 Hct0.311 L/L0.370–0.520
 PLT89 109/L155–435
Renal profile
 Urea5.2 mmol/L2.5–7.5
 Creatinine75 umol/L64–115
 e-GFR>60 mL/min/1.73 m2 >60
 Potassium3.6 mmol/L3.5–5.0
 Sodium124 mmol/L134–147
 Chloride94 mmol/L98–111
Liver function test
 ALT15 U/L10–45
 AST64.2 U/L10–45
 Albumin25 g/L32–48
 Total bilirubin29 umol/L0.0–21.0
Glucose
 Random glucose5.60 mmol/L2.7–18.0
Cardiac enzymes
 CK83 U/L24–195
 Troponin T0.022 ug/L0.01–0.10
Others
 CO2 18 mmol/L22–31
 Lactic acid3.93 mmol/L0.9–1.8

CBC Complete blood count; WBC White blood cell count; Hb Hemoglobin; Hct Hematocrit; PLT Platelets; e-GFR estimated Glomerular filtration rate; CK Creatine kinase; CO 2 Carbon dioxide

Laboratory test results on admission CBC Complete blood count; WBC White blood cell count; Hb Hemoglobin; Hct Hematocrit; PLT Platelets; e-GFR estimated Glomerular filtration rate; CK Creatine kinase; CO 2 Carbon dioxide The chest X-ray showed a diffuse miliary shadowing in both lungs suggestive of tuberculosis. There was mild ground-glass attenuation, especially in the right para-cardiac region. The heart was normal in size with CRT-D leads in place. There was no pleural effusion seen (Fig. 1).
Fig. 1

Posterior anterior and lateral chest X-ray showing diffuse miliary shadowing in both lungs (Arrows). The cardiac resynchronization therapy-defibrillator device and leads in place

Posterior anterior and lateral chest X-ray showing diffuse miliary shadowing in both lungs (Arrows). The cardiac resynchronization therapy-defibrillator device and leads in place The high-resolution computed tomography (CT) chest was consistent with miliary TB. There was no axillary, hilar or mediastinal lymphadenopathy (Fig. 2).
Fig. 2

Computed tomography (CT) chest axial plane showing diffuse randomly distributed ground-glass nodules (blue arrows) involving bilateral lungs consistent with military tuberculosis. Implantable cardioverter defibrillator leads seen (yellow arrows)

Computed tomography (CT) chest axial plane showing diffuse randomly distributed ground-glass nodules (blue arrows) involving bilateral lungs consistent with military tuberculosis. Implantable cardioverter defibrillator leads seen (yellow arrows) Based on the clinical presentation, the chest X-ray and CT chest findings, he was started on first-line anti-TB therapy in the form of rifampin 600 mg orally once daily, ethambutol 1200 mg orally once daily, pyrazinamide 2000 mg orally once daily, and isoniazid (isonicotinylhydrazide or INH) 300 mg orally once daily, with the addition of vitamin B6 25 mg orally once daily, and prednisone 60 mg orally once daily. The trans-thoracic echocardiogram showed moderately dilated LV with severe global hypokinesis and severely reduced function (LVEF <25 %).The CRT-D device leads were seen in the right atrium and right ventricle. There were no obvious masses on the leads or on any of the cardiac valves to suggest vegetations. There was mild to moderate mitral regurgitation. The right ventricular systolic pressure was elevated at 30–40 mmHg. There was no pericardial effusion. The transesophageal echocardiogram was performed, and it showed a mass in the superior vena cava (SVC) around the CRT-D device leads, extending into the right atrium (RA). A thin flickering structure consistent with a remnant of a Eustachian valve or Chiari network was also noted. No masses were seen on them to suggest free moving vegetations on other parts of the leads, but some thickening was seen on one segment of wire. It was very thin and could represent a fibrin/fibrous tissue deposit. No masses were seen on any of the four valves. A small pericardial effusion was seen and “tissue” lines in the visceral pericardium were seen which could be fibrin, a hematoma, or tissue related to tuberculosis pathology (Fig. 3).
Fig. 3

Transesophageal echocardiogram at mid esophageal level showing mass in the right atrium attached to the lead

Transesophageal echocardiogram at mid esophageal level showing mass in the right atrium attached to the lead The blood cultures and urine culture were all negative. The work up was negative for HACEK group (Haemophilus species, Aggregatibacter species, Cardiobacterium hominis, Eikenella corrodens, and Kingella kingae), and other bacterial and viral infection including human immunodeficiency virus (HIV) and respiratory viruses. Bronchoscopy and bronchoalveolar lavage were performed, and pathology examination showed a necrotizing granulomatous inflammation and special stains for AFB were positive. The culture showed Mycobacterium tuberculosis and sensitivity came back as sensitive to all first line anti-TB therapy. His clinical course was complicated by acute renal failure with an increase in serum creatinine to 351 μmol/L and urea to 37 mmol/L. It was felt that the cause of his renal impairment was due to cardio-renal syndrome. It improved gradually and he did not require hemodialysis. He also had confusion and was noted to have a tonic–clonic seizure disorder. He was intubated, put on mechanical ventilation and started on anti-seizure treatment with IV levetiracetam (keppra) and phenytoin. Electroencephalogram showed a severe diffuse encephalopathy with periodic epileptiform discharges and continuous slow activity, generalized (delta coma). CT brain showed a preserved gray-white matter differentiation with no evidence of acute established territorial infarction, intra-axial or extra-axial hemorrhage, hydrocephalus, mass effect, or midline shifting. Lumbar puncture was performed and cerebrospinal fluid (CSF) analysis showed a pale yellow, slightly turbid fluid with labs of: RBC 110 (normally 0), WBC 300 × 109/L (0–5 × 106/L) with neutrophils 72, band 1, lymphocytes 22, and monocytes 5. Glucose was 0.12 mmol/L (2.2–3.90 mmol/L), and protein 3580 mg/L (150–450 mg/L). Mycobacterium tuberculosis complex DNA was positive and Mycobacterium tuberculosis complex was isolated from the CSF. These findings were consistent with TB meningitis. Furthermore, he had melena with a drop in his hemoglobin to 69 g/L. He required transfusion of two units of packed red blood cells (PRBC). Upper gastroenterology endoscopy was performed, and it revealed a duodenal ulcer, which was cauterized. His thrombocytopenia continued and platelets dropped further to 14 × 109/L. Hematology service was involved and it was felt that his thrombocytopenia was secondary to his TB infection. Coombs test was positive and peripheral blood smear showed no significant schistocytes making thrombotic thrombocytopenic purpura (TTP) unlikely. It was decided to remove his CRT-D device leads surgically due to the large size of the vegetations. Once he was relatively stable he was taken to the operating room and under general anesthesia a median sternotomy was performed and he was put on cardiopulmonary bypass machine. The RA was opened and the vegetation was noted to extend from the SVC to mid-RA (Fig. 4).
Fig. 4

Vegetation on the lead

Vegetation on the lead The vegetation was removed and sent for culture and sensitivity. The three leads were removed completely. Cardiopulmonary bypass was weaned off gradually with no difficulty. The patient tolerated the procedure and was transferred to the Cardiac Surgery Intensive Care Unit (CSICU) on inotropic support. The microbiology test of the vegetation revealed 10 colonies of Mycobacterium tuberculosis complex. In the CSICU, he was noted to have a high-grade fever and hemodynamic instability despite maximum inotropic support. He ultimately went into a multi-organ failure and died a few days later.

Discussion

We are presenting a case of miliary tuberculosis (TB) with infective endocarditis involving cardiac resynchronization therapy device leads. We believe that this patient had a miliary TB that was complicated by infection of the CRT-D devices leads due hematogenous spread. There was no evidence of device pocket infection and miliary TB preceded the CDR-IE. Infection of CIEDs is a serious cardiovascular disease which is associated with a high mortality. The incidence of CIEDs infection in a population-based study is 1.9 per 1000 device-years with a higher probability of infection after implantable cardioverter defibrillator (ICD) compared with permanent pacemaker (PPM) implantation [4]. The diagnosis and management of CIEDs infections are difficult [5]. Local device infection is defined as an infection limited to the pocket of the cardiac device and is clinically suspected in the presence of local signs of inflammation at the generator pocket, including warm site, erythema, fluctuance, wound dehiscence, erosion, tenderness or purulent drainage [6]. CDR-IE is defined as infection extending to the electrode leads, cardiac valve leaflets or endocardial surface [1]. As stated above our patient clearly had a CDR-IE secondary to hematogenous spread of the miliary TB. Several factors have been associated with CIED infections, which may be divided firstly into patient factors such as renal failure, corticosteroid use, congestive heart failure, hematoma formation, diabetes mellitus, anticoagulation use, and fever within the 24 h before implantation [6-11]. Secondly, procedural factors such as the type of intervention [12, 13], device revisions, the site of intervention, the number of indwelling leads, the use of pre-procedural temporary pacing, failure to administer perioperative antimicrobial prophylaxis [14], and operator experience [11] all play a role. Our patient had a CRT-D device with three leads which put him at higher risk for CIED infection. In terms of microbiological causes of CDR-IE, Staphylococci especially Coagulase-Negative species (CoNS), accounts for 60–80 % of cases in most of the reported series [15, 16]. A variety of CoNS species have been described [6, 15]. Corynebacterium spp., Propionibacterium acnes, Gram-negative bacilli and Candida spp. are rarely identified as pathogens in CIED infection [6, 15]. CIED infection due to Mycobacterium species is an uncommon but a well-recognized entity. Review of literature showed 25 case reports of CIED related infections due to Mycobacterium species [17-39], with two different Mycobacteria species in one patient [20], and three cases in one report [31]. Tables 2 and 3 show Mycobacterial infections of implanted pacemakers and ICDs respectively, as reported in literature. The infection was mostly pocket infection and rarely bacteremia with leads involvement. The infection occurred between 8 days and 20 years from the last device related procedure. It occurred with both transvenous [17, 18, 20–22, 24–27, 30, 31, 33–39] and epicardial device implantations [19, 23, 28, 29, 32]. Mycobacterium tuberculosis was reported in seven cases [18, 23, 28, 31, 36] with mostly pocket infection. In the two cases with miliary TB, both patients died. The first patient died in hospital after a prolonged admission due to renal and respiratory failure, and recurrent ventricular fibrillation [18]. The second patient died after discharge while awaiting re-implantation of ICD in spite of the fact he had been equipped with a LifeVest [36]. The late presentation, severe systemic involvement, and underlying severe heart failure were key risk factors in our patient’s ultimate outcome. Mycobacterium fortuitum was reported in nine cases [20–22, 24, 26, 27, 30, 38, 39] with pocket infection in five cases and pocket with lead or bacteremia infection in four cases. Mycobacterium abscessus was reported in two cases [19, 33] with pocket infection. Mycobacterium goodii was reported in two cases [25, 29] with pocket infection plus bacteremia in the first case. Mycobacterium avium complex [17], and M. avium intracellulare complex [32] in one case causing epicardial PM and ICD pocket infection respectively. Also it was reported with M. chelonae [20], M. peregrinum [34], and M. phlei [37]. These organisms are commonly found in the environment and likely contaminate the device or pocket at the time of insertion or during surgical manipulation. Reactivation of M. tuberculosis causing a CIED infection has also been identified in some of these case reports [23, 28, 31].
Table 2

Mycobacterial infections of implanted pacemakers as reported in literature

AuthorYearAgeGenderProcedure/Type of deviceType of infectionTime from procedureOrganismClinical presentationManagement/Outcome
Amin et al. [17]199121FPM generator change at the age of 20 years (PM at the age of 7 years)Pocket and proximal leads4 months M. avium complexFever, pain, and swelling over the implant siteDevice extracted by thoracotomy plus antimicrobial therapy (INH, RIF, ETH for 2 weeks)
Doherty et al. [18]199670FVVI PMPocket10 years M. tuberculosis (Miliary TB)Purulent discharge from the pocket and pyrexial illnessDied on her 31st hospital day due to renal and respiratory failure and recurrent VF
Cutay et al. [19]199868MCABG surgery and epicardial pacing leadsPocket and epicardial leads20 years M. abscessus Erythema and discharge from the pocket siteDevice extracted, and antimicrobial therapy (CLR, FOX, AMK for 5 weeks). Patient died about 1 month later due to ESRD
Verghese et al. [20]199874MPMPocket13 days M. chelonae, and M.fortuitum Fever, pain, purulent discharge from PM siteDevice extracted, successful eradication with antimicrobial therapy (GEN, OFX for 1 month)
Sharma et al. [21]200562FBiventricular PMPocket and lead endocarditis Bacteremia9 months M. fortuitum Fever, chills, and pain at PM siteDevice extracted, successful eradication with antimicrobial therapy (DOX, CIP for 6 months)
Hemmersbach-Miller et al. [22]200572MPM in 2005Pocket infection2 weeks1 year laterCoNS and M. fortuitum M. fortuitum AbscessSubcutaneous nodules and chronic drainageDevice extracted, successful eradication with antimicrobial therapy (CIP then CIP, SXT and CLR then AMK and CIP) for 6 months
Hellwig et al. [23]20058Epicardial PM was implanted during CP-A anastomosis surgeryNew epicardial PM 5 weeks laterPocket and epicardial leads11 months6 months M. tuberculosis M. tuberculosis subcutaneous abscess at PM siteFever, and inflammatory syndromeDevice extraction, successful eradication with antimicrobial therapy (RIF, INH, ETH, and PYR 2 months then isoniazid and rifampicin for another 7 months
Pastor et al. (Spanish) [24]200680MDDD-R PMPocket infection Bacteremia18 days (started 1 week before) M. fortuitum Fever, malaise, drowsiness, and purulent dischargeDevice left in situ, successful eradication with antimicrobial therapy (CIP, CLR for 6 weeks)
Toda et al. (Japanese) [25]200686MGenerator change at 82 yearsPocket Bacteremia4 years M. goodii FeverDevice extraction, successful eradication with antimicrobial therapy (INH, RIP and LVX)
Giannella et al. [26]200784FPacemaker upgradePocket1 month M. fortuitum Heart failure, fever, pain and erythema at PM siteDevice extraction, successful eradication with antimicrobial therapy (LVX for 3 months)
Siu et al. [27]200778FDDD PM thenNew DDD PM on right sidePocketEndocarditis3 months M. fortuitum Fever and erosion purulent dischargeOld and new devices extraction, successful eradication (LVX and CLR for 6 months)
Kestler et al. [28]200980FCABG surgery and epicardial pacing wiresPocket and leads11 months M. tuberculosis Painful anterior epigastric massDrainage of abscess cavity and the wires were cut in the abdominal cavity (INH, RIF and ETH for 16 weeks, then INH and RFP total of 25 weeks)
Marchandin et al. [29]200923MA mechanical double valve replacement with epicardial PMPocket infection8-days M. goodii Fever then purulent discharge and wound dehiscenceAntimicrobial treatment (OFX and AMK then DOX) with recovery. PM was not removed
Al Soub et al. [30]200915FPM generator changePocket, leads and myocardiumBacteremia2 months M. fortuitum Discharge from surgical wound site and localized erythema and feverDevice extraction, successful eradication with antimicrobial therapy (DOX, and CIP for 6 months)
Kumar et al. [31]2014a.48b.70c.71MMFDDD PMVVI PMCRT-P(pulmonary tuberculosis 15 years back)Pocket infectionPocket infectionPocket15 months18 months60 months M. tuberculosis M. tuberculosis M. tuberculosis Subcutaneous abscess of the PM siteSubcutaneous abscess at the PM siteLarge lump over the pacemaker siteDevice left in situ antimicrobial therapy (INH,RIF,ETH for 3 months then INH and RIF for another 9 months)PM pocket debridement and antimicrobialTherapy (INH, RIF, ETH and PYR for 3 months then INH and RIF for another 9 months)PM device was explanted, antimicrobialTherapy (RIF, INH, ETH and PYR)

CoNS: a coagulase negative staphylococcus; CP-A: cavopulmonary arterial anastomosis; CRT-P: cardiac resynchronization therapy-pacemaker device; ESRD: end stage renal disease; M: Mycobacteria; PM: pacemaker; TB: Tuberculosis; VF: ventricular defibrillation

Antimicrobial agents: AMK: amikacin; CIP: ciprofloxacin; CLR: clarithromycin; DOX: doxycycline; ETH: ethambutol; IPM: imipenem; LVX: levofloxacin; LZD: linezolid; MEM: meropenem; OFX: ofloxacin; PYR: pyrazinamide; RIF: rifampin; RFP: rifapentine; SXT: trimethoprim-sulfamethoxazole

Table 3

Mycobacterial Infections of implanted cardioverter defibrillators as reported in literature

AuthorYearAgeGenderProcedure/Type of deviceType of infectionTime from procedureOrganismClinical presentationManagement/Outcome
Katona et al. [32]199231FICD, with two epicardial patches and epicardial screw-in leads1 year M. avium-intracellularePain and swelling at the abdominal insertion site of ICDINH, RIF, and ETH and defibrillator leads were relocated to the other side of the abdomen 28 days later
Kessler et al. [33]200453FICDPocket2 weeks M. abscessus Tenderness and brownish odorless dischargeExtraction of the device and CLR for 6 months
Short et al. [34]200574MICDPocket6 weeks M. peregrinum Persistent erythema and a pustuleExtraction of the AICD and the leads. CIP and CLR for 6 weeks
Chrissoheris et al. [35]200885MICD (removal of PM and ICD implantation)PocketFew days M. goodii/smegmatis Erythema, tenderness and fluctuance at the pocket siteextraction of the AICD and the leads and SXT for 8 weeks
Luckie et al. [36]201067MRevision of CRT-DDisseminated TBFew months M. tuberculosis Fatigue, weight loss and anemia then pain around the ICD site, fluctuant swelling 6 months laterThe ICD was explanted, and the patient discharged with a LifeVest and standard anti-tuberculous therapyDied at home
Karnam et al. [37]201173FCRT-DPocket infection1 months M. phlei serosanguinous dischargeThe device and leads were explanted and prolonged antibiotic therapy SXT, DOX for 12 months)
Yuhning et al. [38]201256MUpgrade to a CRT-D from PM then RA lead repositionPocket and leads8 days M. fortuitum worsening pain and wound dehiscence and dischargeAntibacterial treatment (IPM, CLR and MOX; then MEM, LD and DOX) with device and lead extraction. Right MCA stroke, seizures, CoNS bacteremia, acute respiratory failure, and death
Shah et al. [39]201278FICDPocket and lead M. fortuitum Chest wall tenderness, fevers, chills, decreased appetite, weakness and weight lossAntibacterial treatment with device and lead extraction. (SXT for 2 months)
Present case201554MCRT-DLeads6 months M. tuberculosis Miliary TBThe device and leads were explanted and antibiotic therapy. Died due to multi-organ failure

CoNS: coagulase-negative staphylococci; CRT-D: cardiac resynchronization therapy-defibrillator device; ICD: implantable cardioverter defibrillator; MCA: middle cerebral artery

Antimicrobial agents: AMK: amikacin; CIP: ciprofloxacin; CLR: clarithromycin; DOX: doxycycline; ETH: ethambutol; IPM: imipenem; LVX: levofloxacin; LZD: linezolid; MEM: meropenem; OFX: ofloxacin; PYR: pyrazinamide; RIF: rifampin; RFP: rifapentine; SXT: trimethoprim-sulfamethoxazole

Mycobacterial infections of implanted pacemakers as reported in literature CoNS: a coagulase negative staphylococcus; CP-A: cavopulmonary arterial anastomosis; CRT-P: cardiac resynchronization therapy-pacemaker device; ESRD: end stage renal disease; M: Mycobacteria; PM: pacemaker; TB: Tuberculosis; VF: ventricular defibrillation Antimicrobial agents: AMK: amikacin; CIP: ciprofloxacin; CLR: clarithromycin; DOX: doxycycline; ETH: ethambutol; IPM: imipenem; LVX: levofloxacin; LZD: linezolid; MEM: meropenem; OFX: ofloxacin; PYR: pyrazinamide; RIF: rifampin; RFP: rifapentine; SXT: trimethoprim-sulfamethoxazole Mycobacterial Infections of implanted cardioverter defibrillators as reported in literature CoNS: coagulase-negative staphylococci; CRT-D: cardiac resynchronization therapy-defibrillator device; ICD: implantable cardioverter defibrillator; MCA: middle cerebral artery Antimicrobial agents: AMK: amikacin; CIP: ciprofloxacin; CLR: clarithromycin; DOX: doxycycline; ETH: ethambutol; IPM: imipenem; LVX: levofloxacin; LZD: linezolid; MEM: meropenem; OFX: ofloxacin; PYR: pyrazinamide; RIF: rifampin; RFP: rifapentine; SXT: trimethoprim-sulfamethoxazole The widespread use of AFB staining and mycobacterial cultures has undoubtedly increased diagnostic accuracy [40]. Ziehl–Neelsen staining has a sensitivity of 50–80 % while that of blood culture is approximately 98 % [41, 42]. Early identification of the Mycobacterium species can provide predictable antimicrobial susceptibility patterns. The best chance of cure is obtained with a combination of at least two active antimicrobials given for a minimum of 4 weeks, plus removal of the CIEDs [43].

Conclusion

CIEDs infection due to Mycobacterium species is an uncommon but a well-known entity. Early diagnosis and prompt management may result in a good outcome. In case of suspected military TB early initiation of anti-TB therapy is recommended while awaiting culture results.
  41 in total

1.  Complications associated with implantable cardioverter-defibrillator replacement in response to device advisories.

Authors:  Paul A Gould; Andrew D Krahn
Journal:  JAMA       Date:  2006-04-26       Impact factor: 56.272

2.  Unusual chronic pacemaker infection by Mycobacterium tuberculosis in a pediatric patient.

Authors:  Thomas Hellwig; Phalla Ou; Catherine Offredo; Dorothée Stephany; Damien Bonnet; Daniel Sidi
Journal:  J Thorac Cardiovasc Surg       Date:  2005-09       Impact factor: 5.209

Review 3.  Diagnosis of pulmonary tuberculosis in a microbiological laboratory.

Authors:  A El Khéchine; M Drancourt
Journal:  Med Mal Infect       Date:  2011-09-13       Impact factor: 2.152

4.  Microscopic-observation drug-susceptibility assay for the diagnosis of TB.

Authors:  David A J Moore; Carlton A W Evans; Robert H Gilman; Luz Caviedes; Jorge Coronel; Aldo Vivar; Eduardo Sanchez; Yvette Piñedo; Juan Carlos Saravia; Cayo Salazar; Richard Oberhelman; Maria-Graciela Hollm-Delgado; Doris LaChira; A Roderick Escombe; Jon S Friedland
Journal:  N Engl J Med       Date:  2006-10-12       Impact factor: 91.245

5.  The relation between patients' outcomes and the volume of cardioverter-defibrillator implantation procedures performed by physicians treating Medicare beneficiaries.

Authors:  Sana M Al-Khatib; F Lee Lucas; James G Jollis; David J Malenka; David E Wennberg
Journal:  J Am Coll Cardiol       Date:  2005-09-23       Impact factor: 24.094

6.  A patient with relapsing pacemaker infection due to "Gram-positive bacilli".

Authors:  Chung-Wah Siu; Lik-Cheung Cheng; Patrick C Y Woo; Chu-Pak Lau; Hung-Fat Tse
Journal:  Int J Cardiol       Date:  2006-10-27       Impact factor: 4.164

7.  Cardiac device infections due to Mycobacterium fortuitum.

Authors:  Marion Hemmersbach-Miller; Miguel A Cárdenes-Santana; Alicia Conde-Martel; José A Bolaños-Guerra; María I Campos-Herrero
Journal:  Can J Infect Dis Med Microbiol       Date:  2005-05       Impact factor: 2.471

8.  Management and outcome of permanent pacemaker and implantable cardioverter-defibrillator infections.

Authors:  Muhammad R Sohail; Daniel Z Uslan; Akbar H Khan; Paul A Friedman; David L Hayes; Walter R Wilson; James M Steckelberg; Sarah Stoner; Larry M Baddour
Journal:  J Am Coll Cardiol       Date:  2007-04-23       Impact factor: 24.094

9.  Renal insufficiency and the risk of infection from pacemaker or defibrillator surgery.

Authors:  Heather Bloom; Brian Heeke; Angel Leon; Fernando Mera; David Delurgio; John Beshai; Jonathan Langberg
Journal:  Pacing Clin Electrophysiol       Date:  2006-02       Impact factor: 1.976

Review 10.  Myocardial abscess and bacteremia complicating Mycobacterium fortuitum pacemaker infection: case report and review of the literature.

Authors:  Hussam Al Soub; Mona Al Maslamani; Jameela Al Khuwaiter; Yasser El Deeb; Mohammed Abu Khattab
Journal:  Pediatr Infect Dis J       Date:  2009-11       Impact factor: 2.129

View more
  2 in total

Review 1.  Mycobacterium Biofilms.

Authors:  Jaime Esteban; Marta García-Coca
Journal:  Front Microbiol       Date:  2018-01-18       Impact factor: 5.640

2.  Cardiovascular device infections due to rapidly growing Mycobacteria: A review of cases at a tertiary care hospital.

Authors:  Isin Yagmur Comba; Supavit Chesdachai; Hussam Tabaja; Maryam Mahmood; Sharon Deml; Nancy L Wengenack; John W Wilson
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2022-01-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.